Garutti Mattia, Buriolla Silvia, Bertoli Elisa, Vitale Maria Grazia, Rossi Ernesto, Schinzari Giovanni, Minisini Alessandro Marco, Puglisi Fabio
Dipartimento di Oncologia Medica, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy.
Department of Medicine (DAME), University of Udine, 33100 Udine, Italy.
Cancers (Basel). 2020 Jul 17;12(7):1941. doi: 10.3390/cancers12071941.
Despite surgical resection and adjuvant therapies, stage III melanomas still have a substantial risk of relapse. Neoadjuvant therapy is an emerging strategy that might offer superior efficacy compared to adjuvant therapy. Moreover, neoadjuvant therapy has some virtual advantages: it might allow for less demolitive surgery, permit the in vivo evaluation of drug efficacy, help tailor adjuvant treatments, and play a crucial role in innovative translational research. Herein, we review the available literature to explore the scientific background behind the neoadjuvant approach. We also discuss published clinical trials with a focus on predictive biomarkers and ongoing studies. Finally, we outline a possible framework for future neoadjuvant clinical trial development based on the International Neoadjuvant Melanoma Consortium guidelines.
尽管进行了手术切除和辅助治疗，III期黑色素瘤仍有相当大的复发风险。新辅助治疗是一种新兴策略，与辅助治疗相比可能具有更高的疗效。此外，新辅助治疗具有一些实际优势：它可能允许进行创伤较小的手术，能够在体内评估药物疗效，有助于调整辅助治疗方案，并在创新性转化研究中发挥关键作用。在此，我们回顾现有文献，以探索新辅助治疗方法背后的科学背景。我们还将讨论已发表的临床试验，重点关注预测性生物标志物和正在进行的研究。最后，我们根据国际新辅助黑色素瘤联盟指南概述未来新辅助临床试验发展的可能框架。
